Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia.
Sponsor: Apsen Farmaceutica S.A.
Summary
The purpose of this study is to evaluate the efficacy and safety of APSMNF in the treatment of male androgenetic alopecia.
Official title: Phase III Randomized, Multicenter, Double-blind, Parallel Clinical Trial to Evaluate the Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia.
Key Details
Gender
MALE
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
336
Start Date
2026-07-07
Completion Date
2029-08-02
Last Updated
2026-04-08
Healthy Volunteers
No
Conditions
Interventions
APSMNF 1
Administer twice a day during 24 weeks.
APSMNF 2
Administer twice a day during 24 weeks.
Eniagor®
Administer twice a day during 24 weeks.
Locations (1)
Clinica Geral Investiga Ltda
Campinas, São Paulo, Brazil